Abstract
Drug development is a high cost and laborious process, requiring a number of tests until a drug is made available in the market. Therefore, the use of methods to screen large number of molecules with less cost is crucial for faster identification of hits and leads. One strategy to identify drug-like molecules is the search for molecules able to interfere with a protein function, since protein interactions control most biological processes. Ideally the use of in silico screenings would make drug development faster and less expensive. Currently, however, the confirmation of biological activity is still needed. Due to the complexity of the task of drug discovery, an integrated and multi-disciplinary approach is ultimately required. Here we discuss examples of drugs developed through a combination of in silico and in vitro strategies. The potential use of these methodologies for the identification of active compounds as well as for early toxicity and bioavailability is also reviewed.
Keywords: Protein target, drug development, in silico screening, in vitro screening, pharmacokinetics
Current Drug Targets
Title: In Silico and In Vitro: Identifying New Drugs
Volume: 9 Issue: 12
Author(s): Ivani Pauli, Luis Fernando Saraiva Macedo Timmers, Rafael Andrade Caceres, Milena Botelho Pereira Soares and Walter Filgueira de Azevedo Jr.
Affiliation:
Keywords: Protein target, drug development, in silico screening, in vitro screening, pharmacokinetics
Abstract: Drug development is a high cost and laborious process, requiring a number of tests until a drug is made available in the market. Therefore, the use of methods to screen large number of molecules with less cost is crucial for faster identification of hits and leads. One strategy to identify drug-like molecules is the search for molecules able to interfere with a protein function, since protein interactions control most biological processes. Ideally the use of in silico screenings would make drug development faster and less expensive. Currently, however, the confirmation of biological activity is still needed. Due to the complexity of the task of drug discovery, an integrated and multi-disciplinary approach is ultimately required. Here we discuss examples of drugs developed through a combination of in silico and in vitro strategies. The potential use of these methodologies for the identification of active compounds as well as for early toxicity and bioavailability is also reviewed.
Export Options
About this article
Cite this article as:
Pauli Ivani, Macedo Timmers Fernando Saraiva Luis, Caceres Andrade Rafael, Pereira Soares Botelho Milena and de Azevedo Jr. Filgueira Walter, In Silico and In Vitro: Identifying New Drugs, Current Drug Targets 2008; 9 (12) . https://dx.doi.org/10.2174/138945008786949397
DOI https://dx.doi.org/10.2174/138945008786949397 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroscience of Exercise: Association Among Neurobiological Mechanisms and Mental Health
CNS & Neurological Disorders - Drug Targets The Role of Oxytocin in Neuropsychiatric Disorders
Current Medicinal Chemistry Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
Current Neuropharmacology Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery A Case of Toxic Epidermal Necrolysis Secondary to Acetaminophen in a Child
Current Drug Safety Protein Chimera-based Ca2+ Rewiring as a Treatment Modality for Neurodegeneration
Current Psychopharmacology Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry Editors Perspective (Throwing Caution to the Wnts)
Current Neurovascular Research An Overview on Benzylisoquinoline Derivatives with Dopaminergic and Serotonergic Activities
Current Medicinal Chemistry Creating Chemical Diversity to Target Protein Kinases
Combinatorial Chemistry & High Throughput Screening Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: State of the Art
Current Respiratory Medicine Reviews Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
Current Alzheimer Research Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology FOREWORD
Current Neuropharmacology Glyoxal Induced Transition of Transferrin to Aggregates: Spectroscopic, Microscopic and Molecular Docking Insight
Current Pharmaceutical Biotechnology